FilingsTodayJW Lifescience
At a glance
JW Lifescience filed 26 disclosures in the last 12 months, including 4 5% holder and 3 earnings. The most recent key filing was on Aug 12.
Revenue for 2025 was ₩258B, up 15.9% on 2024. Operating margin was 12.9% against 16.1% a year earlier. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩127B and operating profit of ₩18.7B.
The 2025 annual report lists 319 employees with an average tenure of 9.2 years and average pay of ₩68M, #656 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩67M each on average. It paid ₩550 per common share in cash dividends, against ₩500 a year earlier (+10%). JW홀딩스 and related parties held 43.09% at year end.
From the 2025 annual report
Staff: 319 (232 men, 87 women), of whom 30 on fixed-term contracts. Total pay for the year: ₩22.4B. Directors and auditors: 4, paid ₩269M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩550 | ₩500 | ₩500 |
| Payout ratio | 29.8% | 17.6% | 27.5% |
| Yield (as filed) | 4.40% | 4.40% | 3.80% |
| Total cash dividends | ₩8.5B | ₩7.7B | ₩7.7B |
Largest shareholder
JW홀딩스 holds 42.98%; with 4 related parties the group holds 43.09% of common shares at year end.
Auditor: 한영회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.